Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Informations

Home » Informations
  • Bladder-Sparing vs. Radical Cystectomy – Prof. Liangyou Gu Shares Insights at EAU25

    At hashtag#EAU25 in Madrid, we had the opportunity to interview Professor Liangyou Gu from the General Hospital of the Chinese PLA, who shared his clinical perspective on emerging treatment strategies for muscle-invasive bladder cancer (MIBC). With ongoing breakthroughs in MIBC research, bladder-sparing approaches are gaining traction alongside radical cystectomy. Prof. Gu offered his insights on…

    2025.04.10
  •  EAU25 Interview Highlights | Prof. Samson Chan & Prof. Junlong Zhuang on PARPi in mHSPC

    At the 2025 EAU Congress, Prof. Junlong Zhuang (Nanjing Drum Tower Hospital) and Prof. Samson Chan (Department of Surgery, Tuen Mun Hospital, Hong Kong) sat down with Urology Frontier to discuss new insights from the Phase II PROact study. The study evaluated a triple combination of olaparib + abiraterone + prednisone in metastatic hormone-sensitive prostate…

    2025.04.10
  • ELCC 2025 | Dr. Antonio Passaro Discusses TKI Combination Therapy as Standard First-Line Treatment for EGFR-Mutant NSCLC

    At the 2025 European Lung Cancer Conference (ELCC), Professor Antonio Passaro from the European Institute of Oncology (IEO), Italy, led a deep discussion during the controversy session on the topic, “Optimizing the first-line treatment of EGFR-mutant NSCLC: Has the time for TKI combinations arrived?”

    2025.04.10
  • EAU 2025 | Exploring Non-invasive Diagnosis and Combination Therapy for Renal Cancer — Professor Xiongjun Ye’s Team Advances Clinical Practice

    1. UroStream: MRI has rapidly developed, but challenges remain in accurately identifying renal tumors. What advancements has your team made in this area? Professor Xiongjun Ye: Currently, the diagnosis of…

    2025.04.10
  • SGBCC 2025丨Professor Cicero Urban: New Perspectives—Redefining the Patient Population for Axillary Surgery in Early Breast Cancer

    Oncology frontier: The current applicability of axillary surgery (such as SLNB or ALND) in early-stage breast cancer is a subject of controversy. In your report at SGBCC, you mentioned that…

    2025.04.10
  • SGBCC 2025 | Professor Cuizhi Geng: Multiple Posters Presented, China’s Innovations Take the Global Stage

    Oncology Frontier: Your hospital presented multiple posters at this year’s SGBCC. Could you share some of the most notable advances? How will these posters contribute to the global development of…

    2025.04.10
  • From Data to Practice: Dr. Chiu Ka Fung Peter Discusses mHSPC Findings at EAU25

    2025.04.10
  • EAU 2025 | Optimizing Prostate Biopsy Approaches: Prof. Kan Gong’s Team’s Peri-lesion Biopsy RCT Study Awarded at EAU

    At the 40th Annual European Association of Urology (EAU) Congress, precision biopsy strategies and technological innovation were core topics in the prostate cancer field. With a focus on addressing the limitations of traditional systematic biopsies and MRI-targeted biopsies, multiple studies concentrated on optimizing biopsy approaches to balance diagnostic efficacy and safety. “UroStream” invited Professors Kan…

    2025.04.10
«previous next»
Recent Posts
  • Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate
  • Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate
  • Professor Xinan Sheng: Advancing ADC Sequencing Strategies to Overcome Drug Resistance
  • Advancing Precision Therapy in Urothelial Carcinoma: A Collaborative Study by Professors Xuesong Li, Qi Tang, Jianhua Zhang, and Xiaoying Li Explores a Novel Approach to HER2 Assessment
  • Disitamab Vedotin–Based Combination Strategy Redefines First-Line Treatment for Advanced Urothelial Carcinoma, Nearly Doubling Overall Survival
Recent Comments
    Archives
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top